000284983 001__ 284983
000284983 005__ 20240918131817.0
000284983 0247_ $$2doi$$a10.1002/pbc.30742
000284983 0247_ $$2pmid$$apmid:37880926
000284983 0247_ $$2ISSN$$a1545-5009
000284983 0247_ $$2ISSN$$a1545-5017
000284983 037__ $$aDKFZ-2023-02167
000284983 041__ $$aEnglish
000284983 082__ $$a610
000284983 1001_ $$00000-0001-9551-2399$$aSparber-Sauer, Monika$$b0
000284983 245__ $$aRadiotherapy and long-term sequelae in pediatric patients with parameningeal rhabdomyosarcoma: Results of two Cooperative Weichteilsarkom Studiengruppe (CWS) trials and one registry.
000284983 260__ $$aNew York, NY$$bWiley$$c2024
000284983 3367_ $$2DRIVER$$aarticle
000284983 3367_ $$2DataCite$$aOutput Types/Journal article
000284983 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1726658269_11602
000284983 3367_ $$2BibTeX$$aARTICLE
000284983 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000284983 3367_ $$00$$2EndNote$$aJournal Article
000284983 500__ $$a2024 Jan;71(1):e30742
000284983 520__ $$aParameningeal location of rhabdomyosarcoma (PM RMS) is known to be an unfavorable prognostic factor. Scarce data are available on radiotherapy (RT) concepts with regard to outcome.Treatment and outcome of 395 children with PM RMS registered within two Cooperative Weichteilsarkom Studiengruppe (CWS) trials and one registry (1995-2021) were evaluated.Patients were IRS group II (n = 15) and III (n = 380) and received systemic treatment according to the enrolled protocols: I2VA (n = 172), VAIA/CEVAIE (n = 223). Delayed resection was performed in 88/395 (22%) patients, and RT was additionally given in 79/88 (90%) resected patients. RT was the predominant local treatment in 355/395 (90%) patients: hyperfractionated accelerated photon (HART; n = 77), conventionally fractionated photon (n = 91) or proton beam (n = 126), brachytherapy (n = 4), heavy ions (n = 1), not available (n = 56). In the subgroup of RT as only local treatment (n = 278), no intracranial tumor extension and complete remission at end of treatment were significant positive prognostic factors. No significant difference on tumor outcome was seen between different radiotherapy concepts. Long-term toxicity with mostly endocrinological and visual deficiencies was reported in 161/279 (58%) surviving patients with a lower trend after proton beam RT (48%) when compared to HART or conventionally fractionated photon RT (71% and 72%, respectively). Ten-year event-free and overall survival in the overall group were 62% (±5, 95% confidence interval [CI]) and 67% (±5, 95% CI); in the RT-only group 67% (±6, 95% CI) and 71% (±6, 95% CI), respectively.CWS data confirm the recent RT concept in PM RMS. Long-term sequelae as endocrinological and visual deficiencies need to be addressed.
000284983 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000284983 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000284983 650_7 $$2Other$$aCWS Group
000284983 650_7 $$2Other$$achildren and adolescents
000284983 650_7 $$2Other$$aparameningeal rhabdomyosarcoma
000284983 650_7 $$2Other$$aproton beam irradiation
000284983 7001_ $$aDietzschold, Maximilian$$b1
000284983 7001_ $$aSchönstein, Anton$$b2
000284983 7001_ $$aHeinz, Amadeus$$b3
000284983 7001_ $$00000-0002-4138-4536$$aVokuhl, Christian$$b4
000284983 7001_ $$0P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aPajtler, Kristian$$b5$$udkfz
000284983 7001_ $$0P:(DE-HGF)0$$aHarrabi, Semi$$b6
000284983 7001_ $$aLin, Yi-Lan$$b7
000284983 7001_ $$aKalle, Thekla von$$b8
000284983 7001_ $$aHagen, Rudolf$$b9
000284983 7001_ $$aLadenstein, Ruth$$b10
000284983 7001_ $$aKazanowska, Bernarda$$b11
000284983 7001_ $$aLjungman, Gustaf$$b12
000284983 7001_ $$aKlingebiel, Thomas$$b13
000284983 7001_ $$00000-0002-4229-8058$$aEbinger, Martin$$b14
000284983 7001_ $$00000-0002-1519-7569$$aKoscielniak, Ewa$$b15
000284983 7001_ $$aMünter, Marc$$b16
000284983 7001_ $$0P:(DE-HGF)0$$aTimmermann, Beate$$b17
000284983 7001_ $$aGroup, CWS Study$$b18$$eCollaboration Author
000284983 773__ $$0PERI:(DE-600)2130978-4$$a10.1002/pbc.30742$$gp. e30742$$n1$$pe30742$$tPediatric blood & cancer$$v71$$x1545-5009$$y2024
000284983 909CO $$ooai:inrepo02.dkfz.de:284983$$pVDB
000284983 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000284983 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000284983 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000284983 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000284983 9141_ $$y2023
000284983 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2023-08-31$$wger
000284983 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-31
000284983 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-08-31
000284983 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-31
000284983 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPEDIATR BLOOD CANCER : 2022$$d2023-10-25
000284983 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-25
000284983 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-25
000284983 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-25
000284983 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-25
000284983 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-25
000284983 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-25
000284983 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-25
000284983 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000284983 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000284983 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x2
000284983 9201_ $$0I:(DE-He78)ED01-20160331$$kED01$$lDKTK Koordinierungsstelle Essen/Düsseldorf$$x3
000284983 980__ $$ajournal
000284983 980__ $$aVDB
000284983 980__ $$aI:(DE-He78)B062-20160331
000284983 980__ $$aI:(DE-He78)HD01-20160331
000284983 980__ $$aI:(DE-He78)E050-20160331
000284983 980__ $$aI:(DE-He78)ED01-20160331
000284983 980__ $$aUNRESTRICTED